Edition:
United Kingdom

Aimmune Therapeutics Inc (AIMT.OQ)

AIMT.OQ on NASDAQ Stock Exchange Global Select Market

38.44USD
6:14pm GMT
Change (% chg)

$-0.46 (-1.18%)
Prev Close
$38.90
Open
$38.90
Day's High
$39.31
Day's Low
$38.02
Volume
70,461
Avg. Vol
164,723
52-wk High
$40.62
52-wk Low
$15.97

Select another date:

Wed, Jan 10 2018

BRIEF-Aimmune Extends Supply Agreement With Golden Peanut And Tree Nuts For Experimental Allergy Treatment

* AIMMUNE THERAPEUTICS BROADENS AND EXTENDS SUPPLY AGREEMENT WITH GOLDEN PEANUT AND TREE NUTS FOR AR101 FOR PEANUT ALLERGY

BRIEF-Aimmune Therapeutics Inc Files For Potential Mixed Shelf

* AIMMUNE THERAPEUTICS INC FILES FOR POTENTIAL MIXED SHELF, SIZE NOT DISCLOSED - SEC FILING Source text (http://bit.ly/2ClRCUj) Further company coverage:

BRIEF-Aimmune Therapeutics says ‍CEO Stephen Dilly plans to retire by end of 2018​

* Aimmune Therapeutics Inc announces third quarter 2017 financial results and planned retirement of CEO by the end of 2018

Aimmune teams with Regeneron, Sanofi on peanut allergy drug

Aimmune Therapeutics Inc said on Monday it would collaborate with Regeneron Pharmaceuticals Inc and Sanofi to develop its experimental peanut allergy drug.

Aimmune teams with Regeneron, Sanofi on peanut allergy drug

Oct 16 Aimmune Therapeutics Inc said on Monday it would collaborate with Regeneron Pharmaceuticals Inc and Sanofi to develop its experimental peanut allergy drug.

BRIEF-Aimmune Therapeutics collaborates to study AR101 with Regeneron and Sanofi’s dupilumab for peanut allergy

* Aimmune Therapeutics announces clinical collaboration to study AR101 with Regeneron and Sanofi’s dupilumab for peanut allergy

BRIEF-Aimmune Therapeutics qtrly net loss per common share, basic and diluted $0.65

* Aimmune Therapeutics announces second quarter 2017 financial results

Select another date: